Actuate Therapeutics, Inc.
ACTU
$7.22
$0.314.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 196.39% | 129.04% | 31.64% | 17.81% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -13.87% | -16.72% | -2.67% | 46.70% | |
| Operating Income | 13.87% | 16.72% | 2.67% | -46.70% | |
| Income Before Tax | 15.32% | 5.79% | -18.97% | -57.41% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 15.32% | 5.79% | -18.97% | -57.41% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 15.32% | 5.79% | -18.97% | -57.41% | |
| EBIT | 13.87% | 16.72% | 2.67% | -46.70% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 93.49% | 87.12% | -8.06% | -37.37% | |
| Normalized Basic EPS | 93.49% | 88.96% | 6.74% | -29.09% | |
| EPS Diluted | 93.49% | 87.12% | -8.06% | -37.37% | |
| Normalized Diluted EPS | 93.49% | 88.96% | 6.74% | -29.09% | |
| Average Basic Shares Outstanding | 1,200.35% | 631.73% | 10.10% | 14.59% | |
| Average Diluted Shares Outstanding | 1,200.35% | 631.73% | 10.10% | 14.59% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
